Topline data in Q4 2026 is the key catalyst. Monitor for any safety signals or enrollment updates from EMBRACE. The SPRAVATO sales growth ($584M in Q2 2026) supports market demand for novel MDD treatments, but HLP003's Phase 3 data will determine its commercial potential.
Price Chart
Executive Summary
Helus Pharma completed enrollment in the APPROACH Phase 3 pivotal study of HLP003 for Major Depressive Disorder (MDD) ahead of schedule, with topline data expected in Q4 2026. HLP003 has FDA Breakthrough Therapy Designation and Phase 2 data showed a ~23-point MADRS reduction and 100% response rate at 12 months. This is a clinical milestone with no financial data — the stock impact depends on Q4 data readout.
Key Facts
- APPROACH Phase 3 study enrollment completed ahead of schedule with 223 participants.
- Topline data expected in Q4 2026.
- HLP003 has FDA Breakthrough Therapy Designation.
- Phase 2 data: ~23-point mean MADRS reduction from baseline at 12 months after two 16 mg doses.
- Phase 2 data: 100% response and 71% remission rates (MADRS ≤10), rising to 100% remission using ≤12 benchmark.
- EMBRACE, the second pivotal Phase 3 study, continues enrollment.
- EXTEND long-term extension study ongoing for safety and durability data.
- HLP003 is a deuterated psilocin analogue, distinct from SPRAVATO (esketamine).
- Johnson & Johnson reported Q2 2026 SPRAVATO sales of $584M (+40.8% YoY), cited as evidence of market demand.
- Company targets potential FDA NDA submission in 2028.
Financial Impact
No financial data reported; pre-revenue clinical-stage company. Milestone-driven valuation.
Risk Factors
- Phase 3 topline data may fail to replicate Phase 2 efficacy results.
- Regulatory risks: FDA Breakthrough Therapy Designation does not guarantee approval.
- Competition from SPRAVATO and other novel MDD treatments.
- Pre-revenue company with no approved products; financing risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330358 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.19 (+0.79%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.19 (−6.13%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.19 (−7.78%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.19 (−7.78%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.19 (−4.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers